Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
18 stopped studies mapped to Pleural Malignant Mesothelioma and descendants · 100% state a reason
Over the 18 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04158141 | Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy… | Phase 3 | terminated | Nov 8, 2019 | NRG Oncology | Permanent Administrative Closure | Other (stated, no rule matched) |
| NCT04166734 | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant…(MESO-PRIME) | Phase 1 | terminated | Nov 18, 2019 | Royal Marsden NHS Foundation Trust | Study terminated due to slow recruitment and insufficient further funding. | Enrollment / accrual |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | Phase 2 | terminated | Aug 11, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | lack of scientific relevance (change in the treatment landscape) and poor recruitment | Enrollment / accrual |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | Ikena Oncology | Sponsor strategic reasons | Sponsor / business decision |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant… | Phase 2 | terminated | Dec 6, 2013 | Verastem, Inc. | Company decided to discontinue trial to focus on development program next steps | Sponsor / business decision |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung… | Phase 1 / Phase 2 | terminated | Apr 3, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | Phase 2 | withdrawn | Dec 26, 2018 | Health Pharma Professional Research | Publication of study results of ICI use in MPM as first line therapy | Other (stated, no rule matched) |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | Phase 1 | withdrawn | Dec 17, 2019 | Raphael Bueno, MD | Funding complications coupled with competing scientific objectives | Funding |
| NCT02672033 | Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating… | N/A | terminated | Feb 3, 2016 | Jonsson Comprehensive Cancer Center | slow enrollment | Enrollment / accrual |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and… | Phase 1 | terminated | Jun 14, 2010 | National Cancer Institute (NCI) | Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same… | Enrollment / accrual |
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural… | Phase 2 | terminated | Jun 5, 2017 | Aduro Biotech, Inc. | Study was stopped due to low enrollment and lack of clinical activity. | Enrollment / accrual |
| NCT02661659 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With… | Phase 1 | withdrawn | Jan 22, 2016 | University of Chicago | PI stopped study due to inability to accrue. | Enrollment / accrual |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | Phase 2 | terminated | Jun 6, 2013 | Verastem, Inc. | Interim analysis-DSMB stated good safety profile but lack of efficacy | Safety / toxicity |
| NCT02639767 | Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for… | Phase 1 | withdrawn | Dec 24, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00165503 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated… | Phase 2 | terminated | Sep 14, 2005 | Dana-Farber Cancer Institute | lack of acurral | Other (stated, no rule matched) |
| NCT01769547 | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma…(DOVE-M) | Phase 2 | terminated | Jan 16, 2013 | Ontario Clinical Oncology Group (OCOG) | Stage 1 accrual completed. Study did not proceed to Stage 2 accrual. | Enrollment / accrual |
| NCT01353482 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With…(MESO-02) | Phase 1 / Phase 2 | withdrawn | May 13, 2011 | University College, London | UCL CTC were informed by Merck Sharp \& Dohme on 22.08.11 that support for the trial had been… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials